A deal with Sandoz to lead the global launch of Pear’s two lead products puts marketing muscle behind the nascent class of ‘prescription digital therapeutics.’
The OTC launch of Flonase helped drive $294 million in sales, an 80% repeat purchase rate, and 11.4% of the brand dollar share in the adult allergy remedies category (the goal was 7.3%).
Five things for pharma marketers to know: Thursday, September 24, 2015
Mylan’s marketing of EpiPen raises questions about price; the number of drugs approved through expedited pathways is rising; new combo of old drugs may work for Alzheimer’s patients
Five things for pharma marketers to know: Friday, September 4, 2015
Researchers said a new kind of cholesterol-modifying drug from Merck demonstrated remarkably strong LDL-lowering and HDL-raising effects, and appeared safe from a cardiovascular standpoint, stoking doctors’ optimism that it could reach market.
Phase III data reported yesterday at the AHA Meeting in Chicago showed that new blood thinner Xarelto (rivaroxaban) stacks up well against warfarin in preventing strokes in patients with atrial fibrillation.
In Coumadin banter, lessons for marketers of new blood thinners
A love-hate relationship for Coumadin (warfarin) is playing out online, say authors of a new report that may offer lessons for marketers of new blood-thinning products.
Generics and specialty pharma Watson acquired a progesterone gel, marketed as Crinone and Prochieve, and added roughly 19 reps to its women’s health sales force. Watson now employs close to 400 reps, according to Charlie Mayr, a company spokesperson.
Kowa’s US CEO says new statin holds appeal for untreated patients
To those who believe we have everything we need in the lipid-lowering world, Ben Stakely, Kowa Pharmaceuticals America (KPA) CEO and president, has one thing to say: “I would argue with you.”
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix